Drawing for TEIKOKU PHARMA

USPTO serial 79123060

TEIKOKU PHARMA

Reviewed by CopyMark Law Group

Reg. 4416497Status 739Registered
Filing date
Status date
Registration date
Oct 15, 2013
Examiner
MORRIS, KRISTINA KLOIBER
Law office
GENERIC WEB UPDATE

What this means

This trademark is registered with the USPTO. Monitoring new filings can help you catch lookalike marks early.

Need help with TEIKOKU PHARMA?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Bret E. Field

Bret E. Field Bozicevic, Field & Francis LLP201 Redwood Shores Parkway, Suite 200Redwood City, CA 94065United States

Goods and services

ClassDescriptionStatusFirst use
003[ Cosmetics; cosmetic preparations; adhesives for cosmetic purposes; cosmetic masks; soaps for personal use; perfumery; essential oils; hair lotions ]SECTION 71 - CANCELLED—
005Pharmaceuticals for the treatment of cardiovascular conditions, allergies, central nervous system conditions, peripheral nervous system conditions, electrolytic imbalance, caloric imbalance, obesity, vitamin imbalance, gastrointestinal conditions, inflammation, dermatological conditions, infectious diseases, hormonal imbalance, pain, cancer conditions, pulmonary conditions, ophthalmic conditions, musculoskeletal conditions, diabetic conditions, psychosis, senile conditions, dementia, congenital disease conditions, abnormal gene conditions; pharmaceutical preparations, compositions, creams and lotions for the treatment of cardiovascular conditions, allergies, central nervous system conditions, peripheral nervous system conditions, electrolytic imbalance, caloric imbalance, obesity, vitamin imbalance, gastrointestinal conditions, inflammation, dermatological conditions, infectious diseases, hormonal imbalance, pain, cancer conditions, pulmonary conditions, ophthalmic conditions, musculoskeletal conditions, diabetic conditions, psychosis, senile conditions, dementia, congenital disease conditions, abnormal gene conditions; prescription and over-the-counter pharmaceutical preparations for the treatment of cardiovascular conditions, allergies, central nervous system conditions, peripheral nervous system conditions, electrolytic imbalance, caloric imbalance, obesity, vitamin imbalance, gastrointestinal conditions, inflammation, dermatological conditions, infectious diseases, hormonal imbalance, pain, cancer conditions, pulmonary conditions, ophthalmic conditions, musculoskeletal conditions, diabetic conditions, psychosis, senile conditions, dementia, congenital disease conditions, abnormal gene conditions; prescription and over-the-counter pharmaceutical preparations, namely, transdermal gel formulations, transdermal cream formulations, oral mucous formulations, transdermal patches, dressings and medical adhesive tapes for use in the treatment of cardiovascular conditions, allergies, central nervous system conditions, peripheral nervous system conditions, electrolytic imbalance, caloric imbalance, obesity, vitamin imbalance, gastrointestinal conditions, inflammation, dermatological conditions, infectious diseases, hormonal imbalance, pain, cancer conditions, pulmonary conditions, ophthalmic conditions, musculoskeletal conditions, diabetic conditions, psychosis, senile conditions, dementia, congenital disease conditions, abnormal gene conditionsACTIVE—
042Pharmaceutical research and development; pharmaceutical product evaluation, testing and inspection services; providing medical and scientific research information in the field of pharmaceuticals; information, advisory and consultancy services relating to all the aforesaid servicesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
May 28, 2024TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
May 28, 2024ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
May 28, 2024REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
May 11, 2024NA75NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED—
May 11, 2024C75AREGISTERED - SEC. 71 ACCEPTED & SEC. 15 ACK.—
May 7, 2024APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Sep 15, 2023ES75TEAS SECTION 71 & 15 RECEIVED—
Oct 15, 2022REM4COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED—
Oct 6, 2022RNWLINTERNATIONAL REGISTRATION RENEWED—
Oct 17, 2020INNPPARTIAL INVALIDATION PROCESSED BY THE IB—
Sep 5, 2020INPSPARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB—
Aug 26, 2020INPCINVALIDATION PROCESSED—
Jul 21, 2020INPRPARTIAL INVALIDATION OF REG EXT PROTECTION CREATED—
Nov 21, 2019NA75NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED—
Nov 21, 2019C75PREGISTERED - PARTIAL SEC. 71 ACCEPTED & SEC. 15 ACK.—
Nov 21, 2019APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Oct 14, 2019ES75TEAS SECTION 71 & 15 RECEIVED—
Oct 15, 2018REM3COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED—
Jan 9, 2017TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Apr 10, 2014FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Mar 3, 2014FICSFINAL DISPOSITION NOTICE SENT TO IB—
Mar 3, 2014FIMPFINAL DISPOSITION PROCESSED—
Jan 15, 2014FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Oct 15, 2013R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jul 30, 2013PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jul 10, 2013NPUBNOTICE OF PUBLICATION—
Jun 24, 2013PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Jun 17, 2013CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
May 30, 2013TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
May 30, 2013CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
May 22, 2013ALIEASSIGNED TO LIE—
May 20, 2013TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
May 11, 2013CHLDCHANGE OF OWNER RECEIVED FROM IB—
Feb 27, 2013RFNTREFUSAL PROCESSED BY IB—
Jan 28, 2013RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Jan 28, 2013RFRRREFUSAL PROCESSED BY MPU—
Jan 26, 2013RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Jan 25, 2013CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 18, 2013DOCKASSIGNED TO EXAMINER—
Jan 15, 2013MAFRAPPLICATION FILING RECEIPT MAILED—
Jan 9, 2013NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jan 3, 2013REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance